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Objective: To evaluate the characteristics and visual prognosis of juvenile idiopathic 
arthritis-associated uveitis (JIA).
Methods: A retrospective review was performed on 56 patients who met the criteria for JIA to 
identify those with uveitis and related complications. Patients were referred to and were examined 
in the Pediatric Department of the University Hospital of Ioannina, between 1995 and 2007.
Results: The prevalence of JIA-associated uveitis was high. Despite this and the related 
complications, the final visual outcome was satisfactory in the majority of the cases. Authors did 
not observe any correlation between prognosis and sex, age at the onset of uveitis or arthritis, 
pattern of arthritis, or positivity for antinuclear antibodies (ANA).
Conclusion: We found a remarkably high prevalence of uveitis and related ocular complications 
in 7 (28%) of the patients, and the rate of poor visual outcome was 12%.
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Introduction
Juvenile idiopathic arthritis (JIA) is an autoimmune disease1 whose association with 
uveitis is established for more than half a century.2,3,4 There are, according to the 
International League of Associations for Rheumatologists (ILAR), 7 subtypes of JIA 
known as oligoarticular, polyarticular RF(−), polyarticular RF(+), enthesitis-related 
arthritis, psoriatic arthritis, systemic, and undifferantiated.5
The JIA-associated uveitis may develop before, at the same time, or after the arthritis 
onset.2,6 It is typically anterior, chronic, and usually affects both eyes.7–11 If untreated, 
serious ocular complications can occur (cataract, glaucoma, band keratopathy, posterior 
synechiae) causing visual impairment in afflicted children.2,5,12
Risk factors for the development of uveitis in children with JIA, are early onset 
of the disease, pauciarticular subtype, antinuclear antibodies (ANA) positive titers, 
female sex, and certain human leukocyte antigen (HLA) markers.13,14 All children with 
JIA should have at least one adequate slit lamp examination as soon as possible after 
diagnosis of the arthritis.7,12 If uveitis is not detected initially, all children with JIA 
should be screened by slit lamp examination as per specific screening criteria2,3,15,16 
according to the American Academy of Pediatrics (Table 1). We must mention that 
the frequency of ophthalmologic examination has been slightly changed, according 
to updated recommendations,17 where the duration of disease (in years) is also taken 
into consideration.
In the present study we performed a retrospective chart review to study the 
prevalence, complications, and visual outcome of JIA-associated uveitis patients.Clinical Ophthalmology 2010:4 344
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Patients and methods
To identify those with uveitis and related complications a 
retrospective chart review was performed in 56 consecutive 
patients that fulfilled the ILAR 2001 revised criteria for 
juvenile rheumatoid arthritis (JRA):5 persistent arthritis 
(swelling of a joint or limitation of motion with heat, pain, 
or tenderness) of one or more joints for at least 6 weeks after 
exclusion of infectious, metabolic, traumatic, and neoplastic 
causes as well as other autoimmune diseases (including 
psoriatic arthritis, ankylosing spondylitis, inflammatory bowel 
disease, systemic lupus erythematosus). Those patients were 
referred to the Pediatric Department of the University Hospital 
of Ioannina, Greece, between 1995 and 2007 and were exam-
ined ophthalmologically in the Pediatric Ophthalmologic 
Department of our clinic. The pediatric rheumatological 
database included age, gender, arthritis subgroup, age at onset 
of arthritis, treatment, arthritis activity, number of swollen or 
tender joints, and extraarticular manifestations such as the 
presence of uveitis and uveitis complications. The presence 
of antinuclear antibodies (ANA), HLA-B27 antigen, and 
rheumatoid factor (RF) were documented.
The screening intervals met the criteria of the estab-
lished guidelines, at the time patients were examined.18 The 
mean follow up time was 7.5 years. All patients underwent 
a thorough ophthalmologic examination including visual 
acuity or cycloplegic refraction, slit-lamp biomicroscopy, 
IOP measurement (when possible), and dilated-fundus 
examination. Visual acuity cut-offs of 20/50 or worse (low 
vision) and 20/200 or worse (legal blindness) were used 
according to recommendations from the Standardization of 
Uveitis Nomenclature (SUN) Working Group.19
Statistical analysis was performed with Statistical Package 
for Social Sciences (version 14.0; SPSS Inc., Chicago, IL). 
Odds ratios (OR) were calculated using Chi-square tests or 
Fisher’s exact tests where appropriate and P values less than 
0.05 were considered statistically significant.
Results
Fifty-six patients were included in the study with diagnosis 
of JIA. Thirty-seven (66%) were girls and 19 (34%) were 
boys. The average age at diagnosis of JIA was 65 months 
(95% confidence interval [CI]: 51–77 months), range: 
3–161 months, median: 54 months.
Anterior uveitis occurred in 25 (45%) patients during the 
study period. Sixteen (64%) were girls and 9 (36%) were boys. 
It was bilateral in 21 (84%) and unilateral in the other 4 (16%) 
cases. The average age at diagnosis of JIA of the children who 
developed uveitis was 56 months (95% CI: 36–75 months), 
range: 9–152 months, median: 36 months. The prevalence was 
48% (14 of 29) in the patients seen before January 2000 and 
41% (11 of 27) in those seen after January 2000.
The diagnosis of uveitis was made within the first 3 years 
after the diagnosis of JIA for the majority of the patients, 
specifically for 23 (92%) of them.
In 13 (52%) of the 25 patients, uveitis was diagnosed at the 
initial eye examination immediately after diagnosis of JIA, while 
for the remaining 12 (48%) children, the mean interval from the 
diagnosis of JIA to the onset of uveitis was 23 months (95% 
CI 6–41 months), range: 3–89 months, median: 12 months.
Oligoarticular JRA is defined by involvement of 4 or 
fewer joints; polyarticular JRA is defined by involvement 
of 4 joints (usually 10–20); and systemic-onset JRA is 
defined by quotidian fevers during the first 6 weeks of the ill-
ness, almost always associated with a characteristic rash. Of 
the 56 patients with JIA, 42 (75%) were classified as having 
the oligoarticular onset subtype, 10 (18%) as polyarticular 
and 4 (7%) had the systemic onset subtype. Of the 25 patients 
who developed uveitis, 21 (84%) were classified as having 
oligoiarticular onset JIA, 4 (16%) had polyarticular onset 
JIA and none had systemic JIA (Table 2). The subtype of 
JIA did not constitute a statistically signigicant risk factor in 
our study(P-value = 0.17, using the Fisher’s exact test).
Of the 56 patients, ANA titers were positive in 52 (93%) 
and negative in only 4 (7%) of them. Of the 25 patients with 
uveitis, 24 (96%) had positive ANA titers and only 1 (4%) 
had negative ANA titers (Table 3). In this case also, ANA 
positive titers did not constitute a statistically significant risk 
factor (P-value = 0.62, using the Fisher’s exact test).
Table 1 Classification of JIA
Classification of JIA  Frequency of  
eye examination
Risk 
Pauciarticular or polyarticular onset  
7 years of age and AnA (+)
every 3 months high
Pauciarticular or polyarticular  
onset and AnA (−) regardless of age
6 months Medium
Onset 7 years of age, regardless of 
AnA status
6 months Medium
systemic onset of JiA 12 months Low
Abbreviations: AnA, antinuclear antibodies; JiA juvenile idiopathic 
arthntis.
Table 2 Uveitis and JiA subtype
Subtype  Uveitis  
(n = 25)
No uveitis  
(n = 31)
Total  
(n = 56)
Pauci- 21(84%) 21(68%) 42(75%)
Poly- 4(16%) 6(19%) 10(18%)
systemic 0 4(13%) 4(7%)
Abbreviation: JiA, juvenile idiopathic arthritis. Clinical Ophthalmology 2010:4 345
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Visual complications occurred in 7(28%) of the 
25 patients with uveitis (Figures 1–4). Frequencies of poor 
visual acuity at presentation were assessed. Poor visual out-
come occurred in 3(12%) of the patients with uveitis. One 
patient (suffering from phthisis bulbi, see Figure 4) lost vision 
and two others had loss of vision up to counting fingers. None 
of the rest 22(88%) patients had visual acuity less than 7/10, 
while 15(60%) of them had visual acuity equal to 10/10 and 
19(76%) equal or more than 9/10. All these complications 
presented latter in the disease course. Cataract developed in 
six (treated surgically with implantation of anterior chamber 
intraocular lens) and glaucoma in one (initially treated with 
antiglaucomatic drugs and later with trabeculectomy). Four 
patients developed band keratopathy (treated with abrasion 
and use of EDTA), one patient had phthisis bulbi, another 
had hyphema and three developed posterior synechiae 
(Table 4).
Concerning the therapy, 11 children were treated with 
methotrexate, three with a combination of methotrexate 
and methylprednisolone; 10 children were treated with the 
use of biological factors, such as the tumor necrosis factor 
(TNF)-blocking agents etanercept and infliximab; and the 
rest were treated with nonsteroidal anti-inflammatory agents. 
Iridocyclitis was confronted with atropine, anti-inflammatory, 
and cortisone drops.
Discussion
Juvenile idiopathic arthritis is an autoimmune disease that 
can cause great inconvenience in the young patient’s life. The 
prevalence of uveitis at children with JIA,8,9 has been found 
to be between 4% and 24.4%, even though there are sporadic 
studies showing a much greater prevalence. It is typically 
anterior, nongranulomatous, and usually bilateral. Chronic 
iridocyclitis accounts for about 90% of the cases and if 
untreated, serious visual impairment may occur. It is important 
to consider that up to 80% of all cases of anterior uveitis in 
childhood are associated with JIA, thus rendering it the most 
common cause of chronic iridocyclitis in children.19–21
The prevalence of uveitis in our study was 45%. It is one 
of the highest observed in most studies, especially given the 
fact that it concerns all types of JIA and not only selectively 
the oligoarticular. The confusingly different prevalence rates 
observed in the literature, can be attributed to the different 
study designs, as some of them concern population-based 
data and others large rheumatology centers with different 
selection criteria and follow-up. Furthermore, these differ-
ences may derive from the social and environmental factors 
of the patients included in the various studies.
We wanted to find out whether this high rate was due to 
older cases and whether there is a decreasing tendency over 
the last decade. The difference between the two groups was 
quite small. A similar observation was made by Kodsi et al 
in 2002.2
Table 3 AnA titers and uveitis
ANA  
titers
Uveitis  
(n = 25)
No uveitis  
(n = 31)
Total  
(n = 56)
Positive 24(96%) 28(90%) 52(93%)
negative 1(4%) 3(10%) 4(7%)
Abbreviation: AnA, antinuclear antibodies.
Figure 1 Cataract and thin precipite. Figure 2 Posterior subcapsular cataract.Clinical Ophthalmology 2010:4 346
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A significant characteristic of these children is that they 
rarely complain of pain or ‘red eye’, as the onset is often 
asymptomatic and insidious. As uveitis progresses and 
when they begin to complain of visual disturbances, they 
have already developed serious complications (cataract, 
glaucoma, band keratopathy, cystoid macular edema etc).23 
Most patients have seronegative disease for rheumatoid factor 
while the most common serological finding is the presence 
of ANA antibodies which are detected in 96% of uveitis 
cases. ANA titers constitute a nonspecific finding since they 
may be present in other autoimmune diseases, malignancies, 
and aging and they are unassociated with disease activity 
or severity.24 According to studies, the presence of ANA 
should prove useful in identifying patients with JIA at risk 
for chronic anterior uveitis.2
Another significant risk factor is the subtype of JIA. 
80%–90% of cases of JIA-associated uveitis suffer from 
oligoarticular arthritis, 7%–14% from polyarticular and 
2%–6% presents the systemic subtype.19,26
What might be interesting, is the fact that despite the 
established association of uveitis with the presence of oli-
goarticular JIA and presence of antinuclear antibodies,14,26 in 
our study oligoarticular onset subtype of JIA or ANA positive 
titers did not constitute a statistically significant risk factor 
(P  0.05). As in all retrospective studies, our results must 
be interpreted with caution. A referral bias exists because our 
institution is a tertiary care medical center, and it is possible 
that only the most severe cases of JIA associated uveitis were 
referred to our center as suggested by high frequencies of 
ocular complications and poor visual acuity as well as the 
long duration of uveitis prior to presentation to our clinic. 
Furthermore, the number of events was small for some out-
comes, which may have limited the precision of odds ratios 
for certain risk factors. Despite these limitations, our study 
suggests that visual impairment still occur frequently in 
JIA-related uveitis, seen in the tertiary care setting. Almost 
equally high rates of oligoarticular onset subtype of JIA and 
ANA positive titers were found among children who did not 
develop uveitis throughout any stage of the follow up.
In our study visual complications occurred in 7(28%) of 
the 25 patients with uveitis. Severe visual impairment has been 
reported in up to 38% of patients.27–28 Increased severity of 
ocular disease at the initial examination has been reported as a 
risk factor for poor visual acuity outcomes at the last follow-up 
visit, but the follow-up time in these series are variable.29,30
One patient developed uveitis 6 years later and another 
one almost 7.5 years later. Both of them were males, suffering 
from bilateral uveitis, were ANA positive, and HLA-B27 
negative; one suffering oligoarticular and the other from 
polyarticular JIA.
Conclusion
The range of cumulative incidence of JRA-associated uveitis 
has been reported to be between 1.4%–38%.2,31–36 Our analysis 
suggested a cumulative incidence of JRA-associated uveitis at 
the high end of the above mentioned rates. As a conclusion, 
Figure 3 Inflammatory elements on the anterior capsule of the lens.
Figure 4 Phthisis bulbi and hyphema.
Table 4 Visual complications
Visual complications Number of patients(%)
Cataract 6(24%)
glaucoma 1(4%)
Posterior synechiae 3(12%)
Band Keratopathy 4(16%)
Phthisis Bulbi 1(4%)
hyphema 1(4%)Clinical Ophthalmology 2010:4
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we observed remarkably high prevalence of uveitis and related 
ocular complications in 7 (28%) of the patients and furthermore 
the rate of poor visual outcome was almost 12%. The reported 
rate of visual loss due to JRA-related uveitis varies in more 
recent studies from 3%–25%.26 All these documentations may 
facilitate the optimization of the current guidelines and result in 
optimization of follow up. Immediate ophthalmological exami-
nation after the diagnosis of JIA and excellent co-operation 
between the physician and the parents of the children concern-
ing the therapy may help to improve long-term outcome.
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